Silver Book Fact

Antibiotic resistance of Klebsiella pneumoniae on the rise

Resistance of Klebsiella pneumoniae to antibiotics has dramatically increased- from 5.3% to 11.6% for third generation cephalosporins (between 1999 and 2010), and from <0.1% to 4.5% for carbapenams (between 2002 and 2010).

Braykov N, Eber M, Klein E, Morgan D, et al. Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010. Infect Control Hosp Epidemiol. 2013; 34(3): 259-68. https://www.cambridge.org/core/journals/infection-control-and-hospital-epidemiology/article/div-classtitletrends-in-resistance-to-carbapenems-and-third-generation-cephalosporins-among-clinical-isolates-of-span-classitalicklebsiella-pneumoniaespan-in-the-united-states-19992010div/92079FCA7AE739268B12B1EA67759598

Reference

Title
Trends in Resistance to Carbapenems and Third-Generation Cephalasporins Among Clinical Isolates of Klebsiella Pneumoniae in the United States, 1999-2010
Publication
Infect Control Hosp Epidemiol
Publication Date
2013
Authors
Braykov N, Eber M, Klein E, Morgan D, et al.
Volume & Issue
Volume 34, Issue 3
Pages
259-68
URL
Read Full Resource

Categories

  • Cost of Disease
  • Prevalence & Incidence

Related Facts

  • Drug-resistant infections increase length & cost of hospital stays
    Drug-resistant infections increase the length of hospital stays by more than 23% and the cost by close to 30%.  
  • Patients hospitalized for sepsis experience poor outcomes
    Compared with patients hospitalized with other diagnoses, patients hospitalized for sepsis/septicemia are: 1/2 as likely to be discharged home 2 times more likely to be discharged to other short-term care 3 times more…  
  • Mortality rate from hospital-acquired pneumonia
    The mortality rate for hospital-acquired pneumonia ranges from 38% to more than 70%.  
  • Enormous annual direct cost of HAIs to hospitals
    The annual direct cost of healthcare-associated infections to U.S. hospitals ranges from $28.4 billion to $45 billion.  
  • Majority of C. diff deaths in ages 65+
    More than 90% of deaths from C. difficile infectious occur in people ages 65 and older.